P. Chanez (Montpellier, France), P. Paggiaro (Pisa, Italy)
Ozone-induced airway inflammation and its attenuation by corticosteroids are detectable in sputum samples but not in exhaled breath condensate
O. Holz, K. Richter, F. Kanniess, K. J. Simpson, S. J. R. Vessey, P. Linacre, H. Magnussen, R. A. Jörres, R. Tal-Singer (Grosshansdorf, Germany; King of Prussia, United States Of America)
|  |
Exhaled nitric oxide (eNO) levels are reduced by the leucotriene receptor antagonist montelucast in asthmatic children
F. Kirvasilis, E. Hatziagorou, J. Tsanakas (Thessaloniki, Greece)
| |
Aminoguanidine inhibits bronchial NO production, but not diffusion or alveolar NO in patients with asthma, smokers and healthy volunteers
C. Brindicci, P. J. Barnes, S. A. Kharitonov (London, United Kingdom)
| |
Buffering airway acid decreases exhaled nitric oxide levels in humans
B. Gaston, R. Kelly, J. F. Hunt (Charlottesville, United States Of America)
| |
No direct inhibition of NO synthases by montelukast
J. Hamacher, K. Eichert, T. Grebe, C. Braun, R. Lucas, M. Eltze, A. Wendel (Konstanz, Germany)
| |
Non invasive assessment of airway inflammation by exhaled markers in EBC, sputum and NO
G. Becher, M. Rothe, C. Lehmann, R. Eichler (Berlin, Wuerzburg, Germany)
| |
Exhaled nitric oxide in severe obesity
M. Maniscalco, A. Zedda, S. Faraone, E. Troiano, C. Giardiello, G. De Laurentiis, M. Sofia (Casoria, Naples, Italy)
| |
Effects of selective and non-selective cyclooxygenase inhibition on exhaled eicosanoids in COPD
P. Montuschi, F. Macagno, P. Parente, S. Valente, L. Lauriola, C. Mondino, S. A. Kharitonov, P. J. Barnes, G. Ciabattoni (Rome, Chieti, Italy; London, United Kingdom)
| |
Role of sputum eosinophil levels in the assessment of asthma treatment
E. Bacci, A. Di Paco, M. L. Bartoli, E. Garbella, M. Taccola, B. Vagaggini, M. Zingoni, M. De Santis, P. L. Paggiaro (Pisa, Italy)
| |
Acute reversibility of airflow limitation and sputum eosinophilia in chronic obstructive pulmonary disease
M. Tonelli, M. L. Bartoli, F. L. Dente, B. Vagaggini, A. Di Franco, M. Taccola, A. Guerra, P. L. Paggiaro (Pisa, Italy)
| |
Decline of saliva pH at nighttime associated with airway hyperresponsiveness in bronchial asthma
M. Watanabe, K. Tomita, Y. Hasegawa, H. Sano, H. Watanabe, T. Sako, Y. Hitsuda, E. Shimizu (Yonago, Japan)
| |
Cytokine production induced by soluble and particulate stimuli in human peripheral blood mononuclear cells: modulation by pharmacological agents
J. A. Rhodes, G. P. Salmon, M. A. Trevethick, M. Yeadon (Sandwich, United Kingdom)
| |
Effects of N-acetylcysteine and salbutamol on neutrophil migration and release of interleukin-8 and elastase by neutrophils in vitro
A. M. Sadowska, F. J. van Overveld, B. Manuel-y-Keenoy, W. A. De Backer (Antwerp, Belgium)
| |
Effect of montelukast administration on serum IL-5 and total IgE levels in asthmatics
J. Joseph, S. Benedict, W. Safa, M. Joseph (Al Ain, United Arab Emirates)
| |
Immunomodulating activity of inhalations of ultra-low doses of alkylating drug melphalan for severe bronchial asthma treatment
K. A. Zykov, A. L. Pukhalsky, T. I. Grishina, A. V. Rvatcheva, E. I. Sokolov (Moscow, Russia)
| |
Exhaled nitric oxide (NO) in patients with chronic cough
K. Kowal, S. Zukowski, L. DuBuske, A. Bodzenta-Lukaszyk (Bialystok, Poland; Fitchburg, United States Of America)
| |
The influence of steroidotherapy in COPD exacerbation on matrix metalloproteinase MMP-9 level in BAL, induced sputum and serum
R. Rozynska, K. Jahnz-Rozyk, T. Targowski, T. Plusa, A. Chcialowski (Warsaw, Poland)
| |
Complementary effects on IL-1, IL-6, TNF-alpha of salmeterol and/or montelukast added to fluticasone in moderate asthmatics
B. Gemicioglu, H. D. Ikitimur, H. Uzun, S. Aydin, K. Guven (Istanbul, Turkey)
| |
Serum leptin levels in asthmatic children treated with inhaled corticosteroid
F. Gurkan, Y. Atamer, A. Ece, Y. Kocyigit, H. Tuzun, N. Mete (Diyarbakir, Turkey)
| |